Predictors of progression in untreated keratoconus: a Save Sight Keratoconus Registry study.


Journal

The British journal of ophthalmology
ISSN: 1468-2079
Titre abrégé: Br J Ophthalmol
Pays: England
ID NLM: 0421041

Informations de publication

Date de publication:
09 2022
Historique:
received: 20 07 2020
revised: 08 01 2021
accepted: 12 03 2021
pubmed: 1 4 2021
medline: 24 8 2022
entrez: 31 3 2021
Statut: ppublish

Résumé

We set out to identify risk factors for progression in untreated keratoconus patients from 34 centres across Australia, New Zealand, Spain and Italy. Patients were divided into 'progressors' and 'stable' patients for each clinical parameter: visual acuity (VA), steepest keratometry (maximum keratometry (Max-K)) and thinnest corneal thickness (TCT). Primary outcomes were the proportion of eyes with sustained progression in VA, Max-K or TCT within 3 years. Secondary outcomes included predictors of progression. There were 3994 untreated eyes from 2283 patients. The proportion of eyes with VA, Max-K and TCT progression at 1 year were 3.2%, 6.6% and 3.1% respectively. Factors associated with VA loss were higher baseline VA (HR 1.15 per logMAR line increase in VA; p<0.001) and steeper baseline Max-K (HR 1.07 per 1D increase; p<0.001). Younger baseline age was associated with Max-K steepening (HR 0.96 per year older; p=0.001). Thicker baseline TCT, steeper baseline Max-K and younger baseline age were associated with TCT thinning: (HR 1.08 per 10 µm increase in TCT; p<0.001), (HR 1.03 per 1D increase; p=0.02) and (HR 0.98 per year younger; p=0.01), respectively. Steeper Max-K and younger age were the most clinically useful baseline predictors of progression as they were associated with worsening of two clinical parameters. Every 1D steeper Max-K was associated with a 7% and 3% greater risk of worsening VA and thinning TCT, respectively. Each 1 year younger was associated with a 4% and 2% greater risk of steepening Max-K and thinning TCT, respectively.

Identifiants

pubmed: 33785509
pii: bjophthalmol-2020-317547
doi: 10.1136/bjophthalmol-2020-317547
doi:

Substances chimiques

Cross-Linking Reagents 0
Photosensitizing Agents 0
Riboflavin TLM2976OFR

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

1206-1211

Informations de copyright

© Author(s) (or their employer(s)) 2022. No commercial re-use. See rights and permissions. Published by BMJ.

Déclaration de conflit d'intérêts

Competing interests: None declared.

Auteurs

Alex Ferdi (A)

The University of Sydney Save Sight Institute, Sydney, New South Wales, Australia alexander.ferdi@sydney.edu.au.

Vuong Nguyen (V)

The University of Sydney Save Sight Institute, Sydney, New South Wales, Australia.

Himal Kandel (H)

The University of Sydney Save Sight Institute, Sydney, New South Wales, Australia.

Jeremy C K Tan (JCK)

Ophthalmology, Prince of Wales Hospital, Sydney, New South Wales, Australia.

Francisco Arnalich-Montiel (F)

Cornea & External Eye Diseases, Hospital Universitario Ramón y Cajal Biblioteca, Madrid, Spain.

Marco Abbondanza (M)

Abbondanza Eye Center, Rome, Italy.

Stephanie Watson (S)

The University of Sydney Save Sight Institute, Sydney, New South Wales, Australia.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH